Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRM424 in Neurotrophic Keratitis
NCT05927428Phase 2Recruiting
- Sponsor
- BRIM Biotechnology, Inc.
- Start
- Jul 2024
- Primary completion
- Aug 2025
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of BRM421 in neurotrophic keratitis (NK), sponsored by BRIM Biotechnology, Inc.. Started Jul 2024; status: recruiting.
02
Drugs
BRM421
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on NCT05927428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927428.